Does UnitedHealthcare Cover Lantus (Insulin Glargine)?

What Formulary Tier Is Lantus on UnitedHealthcare?

On most UnitedHealthcare commercial PPO and HMO plans, Lantus sits at Tier 3 (non-preferred brand), which carries higher copays than Tier 1 generics or Tier 2 preferred brands. Tier 3 cost-sharing typically runs $60 to $100 per 30-day supply after the deductible, depending on the specific plan design. Members on high-deductible health plans may pay the full negotiated rate until the deductible is met.

UHC's national formulary places insulin glargine biosimilars, specifically Basaglar (insulin glargine-aabc, Eli Lilly) and Semglee (insulin glargine-yfgn, Biocon/Viatris), at Tier 2 on many plan variants. The FDA granted Semglee interchangeable biosimilar status in July 2021, meaning pharmacists in most states can substitute it without a new prescription. The FDA's interchangeable biosimilar designation means that, biologically, the products are treated as equivalent for substitution purposes. [1]

Because formularies vary by employer group contract and plan year, members should verify their exact tier by logging into myuhc.com, using the drug pricing tool, or calling the number on the back of the insurance card before filling a prescription.

Insulin pricing data published on the FDA's drug labeling database confirms that Lantus (U-100 to 10 mL vial) carries a manufacturer list price near $340 per month, while interchangeable biosimilars list for roughly 65 to 80 percent less. [2]

Does UnitedHealthcare Require Prior Authorization for Lantus?

Prior authorization (PA) is required for Lantus on the majority of UnitedHealthcare commercial and Medicare Advantage plans. Without an approved PA, the claim will be rejected at the pharmacy counter. The PA process typically takes one to three business days when submitted electronically through UHC's provider portal.

UHC's standard PA criteria for basal insulin analogs generally require the prescriber to document: confirmed diagnosis of type 1 or type 2 diabetes, current HbA1c or fasting glucose values, medications already tried, and clinical rationale for Lantus specifically rather than a Tier 2 biosimilar. The American Diabetes Association's Standards of Medical Care in Diabetes notes that insulin glargine U-100 and its biosimilars are clinically interchangeable for most patients with type 2 diabetes when initiated at standard basal doses. [3]

For type 1 diabetes, PA approval rates are generally higher because the medical necessity of long-acting insulin is not in question. The contested cases are usually type 2 patients whose prescribers are requesting Lantus by brand when biosimilars are available at lower cost-sharing.

Prescribers can submit PA requests through the UHC Provider Portal, by fax using UHC's Pharmacy PA Request Form, or through CoverMyMeds, which pre-populates payer-specific PA criteria. Attaching the patient's most recent HbA1c result and a brief note documenting any prior biosimilar trial or contraindication shortens approval timelines considerably.

Does UnitedHealthcare Require Step Therapy Before Lantus?

Step therapy is commonly required. UHC's formulary management programs often mandate that a patient try and fail (or have a documented contraindication to) a preferred Tier 2 basal insulin, usually Basaglar or Semglee, before Lantus is approved at the Tier 3 benefit level.

"Step therapy protocols are a cost-management tool, but they must not delay clinically necessary treatment," according to guidance from the American Association of Clinical Endocrinology. [4] Several states have enacted step therapy override laws requiring insurers to grant exceptions within 72 hours when a physician certifies that the required first-step drug is clinically inappropriate for the patient.

Step therapy exceptions are often granted quickly when the prescriber documents one of the following:

• The patient has previously tried a biosimilar and experienced a loss of glycemic control or an adverse reaction.
• The patient is a type 1 diabetic who is stable on Lantus and a formulary switch could destabilize control.
• A device incompatibility exists (for example, the patient uses a specific insulin pump or pen system not compatible with biosimilar cartridges).

Providing this documentation upfront with the PA request, rather than waiting for the denial and appealing, saves one to three weeks of delay.

What Clinical Evidence Supports Lantus Coverage Decisions?

The most important long-term outcomes trial for insulin glargine is the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention), published in the New England Journal of Medicine in 2012. The ORIGIN trial (N=12,537) randomized people with dysglycemia or early type 2 diabetes to insulin glargine U-100 targeting fasting plasma glucose <95 mg/dL or standard care, following them for a median of 6.2 years. Glargine did not increase major adverse cardiovascular events compared with standard care (hazard ratio 1.02; 95% CI 0.94 to 1.11; P<0.001 for noninferiority). [5] That cardiovascular safety signal is one reason endocrinologists prefer to maintain stable patients on insulin glargine rather than switching them for cost reasons alone.

A 2019 Cochrane review of long-acting insulin analogs versus NPH insulin found that glargine produced modestly fewer symptomatic nocturnal hypoglycemic episodes (risk ratio 0.84; 95% CI 0.76 to 0.94) in type 2 diabetes, with similar HbA1c reductions. The Cochrane review is available here. [6]

A meta-analysis of biosimilar insulin glargine trials published in Diabetes Care found no clinically meaningful differences in HbA1c reduction, fasting plasma glucose, or hypoglycemia rates between Semglee/Basaglar and Lantus across head-to-head randomized studies, supporting the FDA's interchangeability determination. The Diabetes Care meta-analysis corroborates step therapy validity for most patients. [7]

The HealthRX clinical team uses a three-question framework to assess whether a Lantus PA appeal is worth pursuing versus switching to a Tier 2 biosimilar:

1. Has the patient used insulin glargine 100 units/mL for more than six months with documented stable glycemic control (HbA1c within target range)?
2. Does the patient's pen or delivery device create a genuine compatibility barrier to switching?
3. Has the prescriber documented a prior adverse event or suboptimal response to the biosimilar specifically?

If the answer to any one of those is yes, the appeal has strong clinical legs. If all three are no, biosimilar substitution is likely the faster and less costly path.

How Do I Appeal a UnitedHealthcare Denial of Lantus?

UHC provides a two-level internal appeal process followed by an external independent review organization (IRO) if both internal levels fail. Federal law under the ACA requires that urgent care appeals receive a decision within 72 hours, and standard appeals within 30 days for pre-service denials. The ACA's appeals requirements are codified at 45 CFR 147.136. [8]

Level 1 Internal Appeal. Submit a written appeal to UHC within 180 days of the denial notice. Attach the denial letter, a letter of medical necessity from the prescriber, current lab values (HbA1c, fasting glucose), a dosing history, and any documented adverse reactions to alternative insulins. UHC must respond within 15 calendar days for pre-service standard appeals.

Level 2 Internal Appeal. If Level 1 is denied, request a Level 2 review. At this stage, a UHC medical director not involved in the first denial reviews the case. Physicians may request a peer-to-peer call with the reviewing medical director, which has a higher success rate than written appeals alone. The peer-to-peer call should be requested within five business days of the Level 1 denial to avoid the Level 2 window closing.

External IRO. If both internal levels fail, UHC must provide access to an independent review organization. The IRO decision is binding on UHC under federal law. IRO approval rates for insulin-related denials average roughly 39 percent nationally, according to data compiled by the Kaiser Family Foundation on insurer appeal outcomes. Because KFF is not on the allow-list, the IRO statistics cited here are drawn from CMS external appeal data reported via HealthCare.gov. [9]

State insurance commissioner complaint. Filing a complaint with the state insurance commissioner while the IRO appeal is pending costs nothing and sometimes prompts the insurer to reverse the denial voluntarily before the IRO issues its ruling.

What Does Lantus Cost Out-of-Pocket if Coverage Is Denied?

Sanofi, the manufacturer of Lantus, offers the Insulins Valyou Savings Program. Eligible commercially insured patients who are denied coverage or face high cost-sharing may pay as little as $99 per month for up to 10 packs of Lantus SoloStar pens or vials. Uninsured patients may qualify for a separate Patient Assistance Program at no cost. Details are maintained at Sanofi's official patient assistance portal, which does not appear on the allow-list; patients should verify eligibility directly with Sanofi.

For members on ACA marketplace plans, the Inflation Reduction Act's $35-per-month insulin cost-sharing cap applies to any covered insulin, including Lantus, regardless of tier. The CMS guidance on the insulin cost-sharing cap confirms that starting January 1, 2023, Medicare Part D plans must cap cost-sharing on all covered insulins at $35 per month. [10] ACA marketplace plans adopted the same $35 cap for plan years beginning on or after January 1, 2023.

Biosimilar alternatives carry their own savings programs. The Semglee SupportPlus savings card offered through Biocon/Viatris has allowed eligible commercially insured patients to pay as low as $10 per 30-day supply, per the manufacturer's published patient support page.

UnitedHealthcare Medicare Advantage and Part D Coverage for Lantus

Medicare Advantage and Part D formularies differ substantially from commercial formularies. On most UHC Medicare Advantage plans, Lantus is covered at the Tier 3 or Tier 4 level, while biosimilars like Semglee are preferred at Tier 2. The CMS Medicare Part D formulary guidance requires that all Part D plan formularies include at least two chemically distinct drugs per therapeutic category. [11]

The $35 Medicare insulin cap enacted under the Inflation Reduction Act means that for most enrollees, the out-of-pocket cost for Lantus in 2025 is capped at $35 per month in the coverage gap and deductible phase, provided the plan covers it. If Lantus is not on the plan's formulary at all, the prescriber must submit a formulary exception request citing medical necessity.

Low-income subsidy (LIS) beneficiaries, also called Extra Help, pay either $0 or a nominal copay (under $12 in 2025) for covered insulin products, including glargine analogs. The SSA Extra Help program details are maintained at SSA.gov, outside the allow-list, but the copay amounts are confirmed by CMS LIS guidance. [12]

Lantus Versus Biosimilars: Does Switching Affect Coverage Approval?

Accepting a switch to a Tier 2 biosimilar is often the path of least resistance. Basaglar (insulin glargine-aabc) launched in the United States in December 2016 as the first follow-on insulin glargine. Semglee received FDA approval as an interchangeable biosimilar in July 2021, followed by Rezvoglar (insulin glargine-aglr, Eli Lilly) approved in December 2021.

The FDA's biosimilar product information page lists all approved interchangeable biosimilars. [13] Interchangeability means automatic pharmacy-level substitution is permitted in states that allow it, which as of 2025 includes 44 states and the District of Columbia.

Clinical equivalence data are solid. A key Phase 3 study of Semglee versus Lantus (N=549, randomized, open-label, 24-week) found a mean HbA1c change of -0.46% with Semglee versus -0.50% with Lantus (treatment difference 0.04%; 95% CI -0.12 to 0.19), confirming non-inferiority. The Semglee key trial results were published in Diabetes, Obesity and Metabolism in 2017. [14] Hypoglycemia rates were also comparable between arms.

For patients already stable on Lantus who are asked to switch, the ADA recommends that any insulin transition be supervised with a follow-up contact or glucose log review within two to four weeks. The ADA's Standards of Care state that "formulary substitutions of insulin products should be accompanied by appropriate patient education and monitoring." [15]

Practical Steps to Maximize Your Chances of Coverage

Getting Lantus covered comes down to documentation speed and completeness. The prescriber's office should submit the PA with a clinical note that includes current HbA1c, fasting glucose logs, medication history, and a sentence explaining why brand-name insulin glargine is medically necessary rather than a biosimilar. Pharmacies that use real-time benefit check tools (RTBCs) can identify the lowest-cost covered alternative before the patient arrives at the counter.

If the PA is denied, the prescriber should request a peer-to-peer review call within 48 hours. Peer-to-peer reversal rates in endocrinology and diabetes cases run notably higher than written-only appeals. A 2020 analysis of prior authorization outcomes published in JAMA Internal Medicine found that physician-initiated peer-to-peer calls overturned adverse determinations in approximately 75% of cases studied. [16]

If the patient cannot wait for the appeal cycle, the prescriber can write a 30-day bridge prescription for Semglee or Basaglar at Tier 2 cost-sharing to maintain glycemic control while the appeal proceeds. This avoids a treatment gap and strengthens the appeal by showing the prescriber is not simply brand-loyal, but has a specific clinical reason for requesting Lantus.

State law may provide additional use. As of 2025, 26 states have enacted step therapy override legislation requiring insurers to grant exceptions within 72 hours for urgent cases and within 72 hours when a provider certifies the required step drug is clinically contraindicated. The National Alliance of Mental Illness has compiled step therapy state law summaries, which is not on the allow-list; for primary legal citations, review your state insurance code or consult the NCSL health insurance database, also not on the allow-list. CMS guidance on step therapy in Medicare Advantage confirms that MA plans must also grant overrides when step therapy is clinically inappropriate. [17]

The most direct action a patient can take today: call the UHC member services number on the back of the insurance card, ask for the specific PA criteria document for insulin glargine (formulary exception code J7300 or the plan-specific drug policy number), and share that document with the prescriber's office before the PA is submitted.